← Back
FeaturedOncologyASCO 20263 endpoints open for prediction

Erleada (apalutamide)

Johnson & Johnson

AR inhibitor in perioperative locally advanced prostate cancer + ADT vs ADT + surgery. PROTEUS Phase 3 at ASCO 2026 plenary LBA1. No efficacy data previously disclosed — pure prediction event. If positive, expands Erleada to earlier-stage disease.

Prostate CancerLocally Advanced
3
Open endpoints

Live Predictions

Pathological Complete Response Rate (pCR %)PRIMARY

The percentage of patients with no residual invasive cancer at surgery. Common primary endpoint in neoadjuvant trials.

Range: 0 – 100 %
Predict →
Readout TBD
Loading…
Hazard Ratio for Overall Survival (OS)PRIMARY

A Hazard Ratio below 1.0 favours the treatment arm. HR 0.75 means a 25% reduction in the risk of death.

Range: 0.4 – 1.2 Hazard Ratio
Predict →
Readout TBD
Loading…
Hazard Ratio for Event-Free Survival (EFS)

A Hazard Ratio below 1.0 favours the treatment arm. HR 0.65 means a 35% reduction in the risk of progression or death.

Range: 0.3 – 1.1 Hazard Ratio
Predict →
Readout TBD
Loading…
Loading comments…

Also Known As

Other names

apalutamide
Search all trials →Request coverage update